Multimorbidity and polypharmacy: Which betablocker to use in relation to the pharmacokinetic profile and interaction potential

Abstract

Betablockers still represent widely prescribed drugs as they cover a wide spectrum of cardiovascular indications. Obviously, it is not trivial which betablocker to choose as they differ both with regard to their pharmacodynamic (e. g. selective vs. nonselective, beta vs. beta + alpha blocking activities) and pharmacokinetic profiles. Latter is largely governed by the metabolic properties, and, thus, their excretion route (renal or biliary route in unchanged or metabolized form). In the elderly population, the stability of plasma concentrations is particularly essential as this population has smaller compensatory tolerance to concentration variations than younger patients. The interaction potential of betablockers with regard to drug-drug, gene polymorphism-drug, excreting organ-drug interactions varies widely between individual substances. Compounds predominantly metabolized by polymorphic cytochromes such as CYP 2D6 are affected by the metabolizer status and competing compounds utilizing the same metabolic pathways can strongly influence plasma levels (examples metoprolol [CAS 37350-58-6], carvedilol [CAS 72956-09-3]). On the other hand, metabolically stable compounds which are predominantly excreted renally may be unfavourable as their plasma concentrations largely depend on renal function which may be blunted in elderly patients. The prototype of this category, atenolol (CAS 29122-68-7), has been associated with inferior results in mortality trials in hypertension treatment.

Thus, a favourable compound should be partially stable in regard to metabolismto depend less on drug-drug and gene-drug interactions, but also utilize more than one routes of excretion, meaning both the direct renal and the metabolic routes. The prototype for this type of betablocker is bisoprolol (CAS 66722-44-9).

Key words

Betablockers - Interactions - Multimorbidity - Polypharmacy

• References

• 1 Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002; 287: 337-44
• 2 Lazarou J, Pomeranz BH Corey PN Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200-5
• 3 World Population Prospects: the 2008 Revision Population Database, medium variant. c 2009 - [cited 26 November 2009]. Available from: http:llesa.un.org/unppl
• 4 Glaeske G, Schicktanz C, Janhsen K. GEK-Arzneimittel-Re-port 2008, Schriftenreihe zur Gesundheitsanalyse. Band 61. St. Augustin (Germany): Asgard-Verlag; 2008
• 5 Franciosa JA. Beta-adrenergic blocking agents: past, present, and future perspectives. Coron Artery Dis. 1999; 10: 369-76
• 6 Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349-55
• 7 Northcote RJ, Ballantyne D. Beta-adrenoceptor blockade and intrinsic sympathomimetic activity-relevance in the treatment of ischaemic heart disease. Scott Med J. 1993; 30: 205-15
• 8 Christ M, Wehling M. Betablocking agents in patients with coronary artery disease and myocardial infarction. In: Böhm M, Laragh J, Zehender P. editors From hypertension to heart failure. Berlin: Springer; 1998: 90-129
• 9 Wagner F, Kalusche D, Trenk D, Jähnchen E, Roskamm H. Drug interaction between propafenone and metoprolol. Br J Clin Pharmacol. 1987; 24: 213-20
• 10 Walley T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet. 1993; 341 (8850) 967-8
• 11 Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol. 2008; 64: 275-82
• 12 Brodde OE, Kroemer HK. Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003; 53 (12) 814-22
• 13 Scheen AJ. Pharma-clinics medication of the month. Nebivolol (Nobiten). Rev Med Liege. 2001; 56: 788-91
• 14 Reynolds RD, Gorczynski RJ, Quon CY. Pharmacology and pharmacokinetics of esmolol. Clin Pharmacol. 1986; 26 (A) A3-A14
• 15 Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther. 1995; 57: 518-24
• 16 Meyer UA. Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc Natl Acad Sci USA. 1994; 91: 1983-4
• 17 Bertilsson L, Dahl ML, Tybring G. Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand. 1997; 391 (Suppl) 14-21
• 18 Poolsup N, LiWanPo A, Knight TL. Pharmacogenetics and Psychopharmacotherapy. J Clin Pharm Ther. 2000; 25: 197-220
• 19 Lewis DF. Watson E, Lake BG. Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutat Res. 1998; 410: 245-70
• 20 Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype-a major determinant of metoprolol metabolism and response. N Engl J Med. 1982; 307: 1558-60
• 21 Wuttke H, Rau T, Heide R, Bergmann K, Bohm M, Weil J et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther. 2002; 72: 429-37
• 22 Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N et al. Effect of CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics. 2002; 12: 465-72
• 23 Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther. 2004; 76: 536-4
• 24 Fux R, Morike K, Prohmer AM, Delabar U, Schwab M, Schaeffeler E et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther. 2005; 78: 378-87
• 25 Shin J, Johnson JA. Pharmacogenetics of betablockers. Pharmacotherapy. 2007; 27: 874-87
• 26 Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004; 18: 113-23
• 27 Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol. 2008; 64: 1163-73
• 28 Horikiri Y, Suzuki T, Mizobe M. Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998; 63: 1097-108
• 29 Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE. Interaction of bisoprolol with cimetidine and rifampicin. Eur J Clin Pharmacol. 1986; 31: 59-62
• 30 Fachinfo Service [Internet]. „Fachinformation” Concor®; c2009 - [updated July 2008; cited 26 November 2009]. Available from: http://www.fachinfo.de/viewFI?FINR=003991&RL=Concor%26reg%3B%205%26nbsp%3Bmg/-10%26nbsp%3Bmg%20Filmtabletten
• 31 Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M et al. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with biso-prolol. J Cardiovasc Pharmacol. 2005; 46: 713-20
• 32 Huang JD, Chuang SK, Cheng CL, Lai ML. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin Pharmacol Ther. 1999; 65: 402-7
• 33 Taguchi M, Nozawa T, Kameyama T, Inoue H, Takesono C, Mizukami A et al. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. Eur J Clin Pharmacol. 2003; 59: 385-8
• 34 POISE Study Group: Devereaux PJ Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC. et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008; 371: 1839-1847
• 35 Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycopro-tein. Fundam Clin Pharmacol. 2006; 20: 273-82
• 36 Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009; 41: 67-76
• 37 McAinsh J, Holmes BF, Smith S, Hood D, Warren D. Atenolol kinetics in renal failure. Clin Pharmacol Ther. 1980; 28: 302-9
• 38 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41
• 39 Calis KA, Young LR. Clinical analysis of adverse drug reactions. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP. editors. Principles of Clinical Pharmacology. San Diego: Academic Press; 2001
• 40 Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, deFaire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359 (9311) 995-1003
• 41 Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding peri-ndopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366 (9489) 895-906
• 42 Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol. 2007; 120: 10-27
• 43 Neutel JM, Smith DHG, Ram CV, Lefkowitz MP, Kazem-pour MK, Weber MW. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Am J Cardiol. 1993; 72: 41-6
• 44 Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007; 24: CD002003
• 45 Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Piatt R. Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. Arch Intern Med. 2008; 168: 2415-21
• 46 Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet. 1987; 13: 110-7
• 47 McGavin JK, Keating GM. Bisoprolol: a review of its use in chronic heart failure. Drugs. 2002; 62 (18) 2677-96
• 48 Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol. 1986; 8 (11) S16-20
• 49 Campeanu A. The cardiac insufficiency talinolol study (CITAS) study design. Eur J Heart Fail. 2001; 3: 377-80
• 50 Broncel M, Chojnowska-Jezierska J, Adamska-Dyniewska H. Bisoprolol in the treatment of hypertension in the elderly. J Hum Hypertens. 1998; 12: 643-4
• 51 Düngen HD, Apostolovic S, Inkrot S, Tahirovic E, Krackhardt F, Pavlovic M et al. Subproject Multicenter Trials in the Competence Network Heart Failure.Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol. 2008; 97: 578-86